Parental and SNCA A53T, GRN R493X and MECP2 HM macrophages expressed high levels of CD47, ’marker-of-self’ protein, is emerging as a novel potent macrophage immune checkpoint for cancer immunotherapy [34]. This evidence concerns the gene MECP2 and cancer.